WITHDRAWN: Intermedin 1-53 Ameliorates Atrial Fibrosis and Reduces Inducibility of Atrial Fibrillation via TGF-β1/pSmad3 and Nox4 Pathways in a Rat Model of Heart Failure

Title:WITHDRAWN: Intermedin 1-53 Ameliorates Atrial Fibrosis and Reduces Inducibility of Atrial Fibrillation via TGF-β1/pSmad3 and Nox4 Pathways in a Rat Model of Heart Failure

Volume: 18

Author(s): Shenzhou Ma, Ximin Wang, Zhan Li and Yinglong Hou*

Affiliation:

• Shandong Qianfoshan Hospital, Cheelou College of Medicine, Shandong University, Jinan, China
• Cardiology departments, The First affiliated Hospital of Shandong First Medical University, Jinan, China

Abstract: Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has been withdrawn.

Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.

The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php

Bentham Science Disclaimer:

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

Cite this article as:

Ma Shenzhou, Wang Ximin, Li Zhan and Hou Yinglong*, WITHDRAWN: Intermedin 1-53 Ameliorates Atrial Fibrosis and Reduces Inducibility of Atrial Fibrillation via TGF-β1/pSmad3 and Nox4 Pathways in a Rat Model of Heart Failure, Current Signal Transduction Therapy 2023; 18 () : e021222211558 . https://dx.doi.org/10.2174/1574362418666221202152035